H. Lundbeck A/S (HLBBF)
| Market Cap | 6.07B +10.9% |
| Revenue (ttm) | 3.87B +11.9% |
| Net Income | 501.82M +1.6% |
| EPS | 0.51 +1.5% |
| Shares Out | n/a |
| PE Ratio | 12.10 |
| Forward PE | 6.55 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 885 |
| Average Volume | 1,417 |
| Open | 5.90 |
| Previous Close | n/a |
| Day's Range | 5.90 - 5.90 |
| 52-Week Range | 4.42 - 7.55 |
| Beta | 0.30 |
| RSI | 44.44 |
| Earnings Date | May 13, 2026 |
About H. Lundbeck
H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati... [Read more]
Financial Performance
In 2025, H. Lundbeck's revenue was 24.63 billion, an increase of 11.93% compared to the previous year's 22.00 billion. Earnings were 3.19 billion, an increase of 1.56%.
Financial numbers in DKK Financial StatementsNews
H. Lundbeck Launches Bid for Avadel in Move to Scuttle Alkermes Deal
The unsolicited bid—worth up to $2.25 billion —potentially upends Avadel's deal to be acquired by Alkermes.
Lundbeck's potential treatment for Multiple System Atrophy granted Orphan Drug Designation in Japan
VALBY, Denmark , March 10, 2025 /PRNewswire/ -- The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a po...